Aan dit artikel is enkele uren gewerkt. Opzoeken, vertalen, plaatsen enz. Als u ons wilt ondersteunen dan kan dat via een al of niet anonieme donatie. Elk bedrag is welkom hoe klein ook. Klik hier als u ons wilt helpen kanker-actueel online te houden. Wij zijn een ANBI organisatie dus uw donatie is in principe aftrekbaar voor de belasting.

9 juni 2012: Bron: Eur J Clin Nutr. 2012 Mar;66(3):399-404. doi: 10.1038/ejcn.2011.214. Epub 2012 Jan 11.

Eiwitsupplement met 2,02 gram EPA en 0,92 gram DHA ( n-3 meervoudig onverzadigde vetzuren (FA)) per dag tijdens de behandelingsperiode (chemo en - of bestraling) verbetert significant de levenskwaliteit bij patiënten met niet-klein-cellige longkanker (NSCLC) Dit blijkt uit een dubbelblinde gerandomiseerde studie uitgevoerd in het VUMC Amsterdam. We hebben voor u het abstract zo goed als letterlijk vertaald. Onderaan staat link naar volledige studierapport en referentielijst

Achtergrond / doelstellingen:
Ons doel was om de effecten van een oraal voedingssupplement dat n-3 meervoudig onverzadigde vetzuren (FA) bevat, te onderzoeken op
kwaliteit van leven, performance status, handgreep kracht en fysieke activiteit bij patiënten met niet-kleincellige longkanker (NSCLC) die een multimodale behandeling ondergaan.

Methoden:
In een dubbelblinde gerandomiseerde studie werden 40 patiënten met niet-klein-cellige longkanker stadium III  gerandomiseerd naar een groep van 20 patiënten die 2 blikjes per dag te drinken kregen van een eiwitrijk en energierijk oraal voedingssupplement dat n-3 meervoudig onverzadigde FA (2,02 g eicosapentaeenzuur + 0.92 g docosahexaeenzuur bevatte. En een groep van 20 patiënten die ook 2 blikjes per dag te drinken kregen maar deze bevatte een zogeheten isocalorisch controle supplement, tijdens de multimodale behandeling.
Kwaliteit van leven, performance status Karnofsky-index, kracht van een handgreep en fysieke activiteit (door het dragen van een accelerometer) werden beoordeeld. Effecten van de interventie werden geanalyseerd door een algemene schatting en vergelijkingen. P-waarden <0,05 werden als significant beschouwd.

Resultaten:
De patiënten in de interventiegroep (met de n-3 meervoudig onverzadigde vetzuren (FA)) scoorden na 5 weken daarbij significant hoger op kwaliteit van leven, fysieke en cognitieve functie (B = 11.6 en B = 20,7, p <0,01), algemene gezondheidstoestand (B = 12.2, P = 0,04) en de sociale functie (B = 22.1, P = 0,04) dan de controlegroep na 5 weken. De interventiegroep toonde ook een hogere Karnofsky Performance Status (B = 5,3, P = 0,04) dan de controlegroep na 3 weken. Handgreep kracht bleek niet significant verschillend tussen de groepen in die 5 weken. De patiënten uit de interventiegroep neigden naar hogere fysieke activiteiten dan de patiënten uit de controlegroep na 3 en 5 weken (B = 6,6, P = 0,04 en B = 2,5, P = 0,05) respectievelijk

Conclusie:
n-3 meervoudig onverzadigde FA kan een gunstige invloed hebben op kwaliteit van leven, performance status en fysieke activiteit bij patiënten met niet-klein-cellige longkanker (NSCLC) die een multimodale behandeling ondergaan.

Het volledige studierapport: Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT kunt u gratis inzien als u hier klikt.

Hier het originele engelstalige abstract:

n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment

Eur J Clin Nutr. 2012 Mar;66(3):399-404. doi: 10.1038/ejcn.2011.214. Epub 2012 Jan 11.

Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT.

Source

Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.

Abstract

BACKGROUND/OBJECTIVES:

Our objective was to investigate effects of an oral nutritional supplement containing n-3 polyunsaturated fatty acids (FAs) on quality of life, performance status, handgrip strength and physical activity in patients with non-small cell lung cancer (NSCLC) undergoing multimodality treatment.

SUBJECTS/METHODS:

In a double-blind experiment, 40 patients with stage III NSCLC were randomised to receive 2 cans/day of a protein- and energy-dense oral nutritional supplement containing n-3 polyunsaturated FAs (2.02 g eicosapentaenoic acid+0.92 g docosahexaenoic acid/day) or an isocaloric control supplement, during multimodality treatment. Quality of life, Karnofsky Performance Status, handgrip strength and physical activity (by wearing an accelerometer) were assessed. Effects of intervention were analysed by generalised estimating equations. P-values <0.05 were regarded as statistically significant.

RESULTS:

The intervention group reported significantly higher on the quality of life parameters, physical and cognitive function (B=11.6 and B=20.7, P<0.01), global health status (B=12.2, P=0.04) and social function (B=22.1, P=0.04) than the control group after 5 weeks. The intervention group showed a higher Karnofsky Performance Status (B=5.3, P=0.04) than the control group after 3 weeks. Handgrip strength did not significantly differ between groups over time. The intervention group tended to have a higher physical activity than the control group after 3 and 5 weeks (B=6.6, P=0.04 and B=2.5, P=0.05).

CONCLUSION:

n-3 Polyunsaturated FAs may beneficially affect quality of life, performance status and physical activity in patients with NSCLC undergoing multimodality treatment.

PMID:
22234041
[PubMed - in process]

PMCID:
PMC3303137

References

  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594. [PMC free article] [PubMed]
  • Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225S–233S. [PubMed]
  • Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20:204–209. [PubMed]
  • De Leyn P, Vansteenkiste J, Lievens Y, Van RD, Nafteux P, Decker G, et al. Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer. J Thorac Oncol. 2009;4:62–68. [PubMed]
  • van Meerbeeck JP, Kramer GW, Van Schil PE, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450. [PubMed]
  • Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers. Br J Cancer. 2004;90:1905–1911. [PMC free article] [PubMed]
  • de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. A prospective study on quality of life of patients with cancer of the oral cavity or oropharynx treated with surgery with or without radiotherapy. Oral Oncol. 1999;35:27–32. [PubMed]
  • Ravasco P, Monteiro-Grillo I, Marques VP, Camilo ME. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck. 2005;27:659–668. [PubMed]
  • Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol. 2011;23:322–330. [PubMed]
  • Barber MD. The pathophysiology and treatment of cancer cachexia. Nutr Clin Prac. 2002;17:203–209.
  • Bennani-Baiti N, Davis MP. Cytokines and cancer anorexia cachexia syndrome. Am J Hosp Palliat Care. 2008;25:407–411. [PubMed]
  • Jho DH, Cole SM, Lee EM, Espat NJ. Role of omega-3 fatty acid supplementation in inflammation and malignancy. Integr Cancer Ther. 2004;3:98–111. [PubMed]
  • Calder PC. Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2007;77:327–335. [PubMed]
  • Guarcello M, Riso S, Buosi R, D'Andrea F. EPA-enriched oral nutritional suport in patients with lung cancer: effects on nutritional status and quality of life. Nutr Ther Metab. 2007;25:25–30.
  • Bayram I, Erbey F, Celik N, Nelson JL, Tanyeli A. The use of a protein and energy dense eicosapentaenoic acid containing supplement for malignancy-related weight loss in children. Pediatr Blood Cancer. 2009;52:571–574. [PubMed]
  • Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer. 2004;90:996–1002. [PMC free article] [PubMed]
  • Fearon KC, von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut. 2003;52:1479–1486. [PMC free article] [PubMed]
  • Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24:3401–3407. [PubMed]
  • Meij van der BS, Langius JAE, Smit EF, Spreeuwenberg MD, von Blomberg BM, Heijboer AC, et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr. 2010;140:1774–1780. [PubMed]
  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. [PubMed]
  • Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Nat Rev Cancer. 1980;45:2220–2224.
  • Karnofsky DA, Burchenal JH. Evaluation of chemotherapeutic agentsIn: MacLeod CM (ed).The Clinical Evaluation of Chemotherapeutic Agents in Cancer Columbia University Press: New York; 1949. p196.
  • Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil. 1985;66:69–74. [PubMed]
  • Slootmaker SM, Chinapaw M, Schuit AJ, van Mechelen W, Koppes LL. Concurrent validity of the PAM accelerometer relative to the MTI Actigraph using oxygen consumption as a reference. Scand J Med Sci Sports. 2009;19:36–43. [PubMed]
  • Ainsworth BE, Haskell WL, Whitt MC, Irwin ML, Swartz AM, Strath SJ, et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000;32:S498–S504. [PubMed]
  • Twisk JW, Kemper HC, Mellenbergh GJ, van Mechelen W, Post GB. Relation between the longitudinal development of lipoprotein levels and lifestyle parameters during adolescence and young adulthood. Ann Epidemiol. 1996;6:246–256. [PubMed]
  • Twisk JW. Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis. Eur J Epidemiol. 2004;19:769–776. [PubMed]
  • Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121–130. [PubMed]
  • Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997;92:215–221. [PubMed]
  • Barber MD, McMillan DC, Preston T, Ross JA, Fearon KC. Metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish-oil-enriched nutritional supplement. Clin Sci (Lond) 2000;98:389–399. [PubMed]
  • Barber MD, Ross JA, Preston T, Shenkin A, Fearon KC. Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer. J Nutr. 1999;129:1120–1125. [PubMed]
  • Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177–184. [PubMed]
  • Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy. Radiother Oncol. 2003;67:213–220. [PubMed]
  • Gupta D, Lis CG, Granick J, Grutsch JF, Vashi PG, Lammersfeld CA. Malnutrition was associated with poor quality of life in colorectal cancer: a retrospective analysis. J Clin Epidemiol. 2006;59:704–709. [PubMed]
  • Isenring E, Bauer J, Capra S. The scored Patient-generated Subjective Global Assessment (PG-SGA) and its association with quality of life in ambulatory patients receiving radiotherapy. Eur J Clin Nutr. 2003;57:305–309. [PubMed]
  • Carlson SE. Early determinants of development: a lipid perspective. Am J Clin Nutr. 2009;89:1523S–1529S. [PMC free article] [PubMed]
  • Coups EJ, Park BJ, Feinstein MB, Steingart RM, Egleston BL, Wilson DJ, et al. Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life. Cancer Epidemiol Biomarkers Prev. 2009;18:664–672. [PMC free article] [PubMed]
  • Lowe SS, Watanabe SM, Baracos VE, Courneya KS. Associations between physical activity and quality of life in cancer patients receiving palliative care: a pilot survey. J Pain Symptom Manage. 2009;38:785–796. [PubMed]
  • Gibney E, Elia M, Jebb SA, Murgatroyd P, Jennings G. Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism. 1997;46:1412–1417. [PubMed]
  • Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M. European Organization for Research and Treatment of Cancer: Brussels; 1999. on behalf of the EORTC Quality of Life Study Group. The EORTC QLQ-C30 Scoring Manual, 2nd edn.

Plaats een reactie ...

Reageer op "Eiwitsupplement met 2,02 gram EPA en 0,92 gram DHA ( n-3 meervoudig onverzadigde vetzuren (FA)) per dag tijdens de behandelingsperiode verbetert significant de levenskwaliteit bij patienten met niet-klein-cellige longkanker (NSCLC)"


Gerelateerde artikelen
 

Gerelateerde artikelen

Referentiegids effecten van >> Algemeen: effecten van voedingswijzen, >> Aminozuren - BCAA verbeteren >> Anti kanker effectiviteit >> Anti-oxidanten via voedingssupplementen >> Antioxidanten hebben geen >> Arts-bioloog drs. E. Valstar >> Arts-bioloog drs. E. Valstar: >> ATRA - all-trans-retinoic-acid >> Avemar, een gefermenteerd >>